No HRR mutations were detected in LGSOC, sarcoma, and borderline serous tumors in this study; 2.7% (4/46) BRCA1 and 1.2% (1/46) other HRR variants were reported in LGSOC in the GOG 218 study (35), and RAD54L was recently reported in one of six LGSOC in a Japanese study (36). This evidence concerns the gene RAD54L and sarcoma.